Showing results (161-170 of 183) with videos related to

Sort By:
Pageof 19
Haematologica|April 21, 2019
Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative studySabine Kayser, Robert K Hills, Marlise R Luskin, et al.
Cancer Cell|October 6, 2009
Proteomic and genetic approaches identify Syk as an AML targetCynthia K Hahn, Jacob E Berchuck, Kenneth N Ross, et al.
Cancer Cell|August 18, 2012
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repressionOmar Abdel-Wahab, Mazhar Adli, Lindsay M LaFave, et al.
Leukemia Research|October 30, 2012
Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosisAdi Diab, Lynette Zickl, Omar Abdel-Wahab, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2024
Mapping the Cellular Biogeography of Human Bone Marrow Niches Using Single-Cell Transcriptomics and Proteomic ImagingShovik Bandyopadhyay, Michael Duffy, Kyung Jin Ahn, et al.
Blood Cancer Journal|August 16, 2022
Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemiaFrançois Vergez, Laetitia Largeaud, Sarah Bertoli, et al.
Blood|June 1, 2026
Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapyVanessa E Kennedy, Cheryl A C Peretz, Anushka Walia, et al.
Cell Reports. Medicine|July 28, 2026
Tumor-induced dendritic cell deregulation perturbs T cell proliferation and predicts clinical outcome in acute lymphoblastic leukemiaAnil Kumar, Kory Hamane, Caroline Duault, et al.
Blood Advances|July 30, 2026
Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AMLMark J Levis, Mehdi Hamadani, Brent R Logan, et al.
Blood|May 7, 2025
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 studyMartha L Arellano, Michael J Thirman, John F DiPersio, et al.
Pageof 19